In the life sciences, the value of any asset under development (e.g., novel therapeutic, diagnostic, platform technology, or health analytics software) will be mainly a function of risk – because cash flows from successful products can be fairly well benchmarked for a given category [1]. As an investor, entrepreneur, or manager in a growth-stage venture, […]